Will Spooren, Ph.D.

Section Head, Behavioural Pharmacology and Preclinical Imaging, F. Hoffmann-La Roche

SFARI Investigator Website

Will Spooren is section head of behavioral pharmacology and preclinical imaging at Hoffman-La Roche. His group is responsible for providing in vivo characterization of drug candidates through the course of drug discovery an`d development process. He co-led the European Autism Interventions – A Multicentre Study for Developing New Medications (EU-AIMS) with Declan Murphy and currently serves as the industry project lead in the Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials).

Read More

Funded Projects

SFARI Funded Publications

Imbalanced social-communicative and restricted repetitive behavior subtypes of autism spectrum disorder exhibit different neural circuitry. Bertelsen N., Landi I., Bethlehem R.A.I., Seidlitz J., Busuoli E.M., Mandelli V., Satta E., Trakoshis S., Auyeung B., Kundu P., Loth E., Dumas G., Baumeister S., Beckmann C.F., Bölte S., Bourgeron T., Charman T., Durston S., Ecker C., Holt R.J., Johnson M., Jones E., Mason L., Meyer-Lindenberg A., Moessnang C., Oldehinkel M., Persico A., Tillmann J., Williams S.C.R., Spooren W., Murphy D., Buitelaar J.K., EU-AIMS LEAP Group, Baron-Cohen S., Lai M.-C., Lombardo M.
Subscribe to our newsletter and receive SFARI funding announcements and news